Hims & Hers (NASDAQ: HIMS) stock has done well since the company went public a few years ago. It has soared by over 193% in ...

Starboard has a roughly $1 billion stake in the drugmaker and approached former Pfizer CEO Ian Read and ex-CFO Frank D'Amelio ...

One of the ingredients responsible for these shopper accolades is citric acid; the beta hydroxy acid (BHA) promotes growth ...

If you're looking to make your hair grow faster, try Viviscal, the most-loved hair supplement by Cosmo readers, which is ...

HIMS is growing at a complete breakneck pace. The main question that looms over its prospects is this. How sustainable are its growth rates? And my answer is that this level of growth is not ...

Of the 22 guru strategies we follow, HIMS rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market ...

If you’re reading this because you’re losing your hair, you’re not alone — hair loss is a common issue affecting more than ...

As demand for products that tackle thinning hair rises, popular prestige brands are reimagining the hair loss category ...

Shares of Hims & Hers Health fell almost 10% today following ... “As the demand continues to grow, there continues to be a shortage of conventionally manufactured product, and compounding ...

Hims & Hers Health, Inc. is an interesting pick because of its innovative approach in the telemedicine industry and its potential for significant growth. The company operates in a sector that ...

Hims & Hers (NYSE:HIMS), the telehealth platform that offers compounded versions of weight loss drugs, dropped more than 10% on Thursday after the FDA confirmed that Eli Lilly's (LLY) GLP-1 ...